Welcome to our dedicated page for iRhythm Technologies news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Technologies stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) is a commercial-stage digital healthcare company redefining the diagnosis of cardiac arrhythmias through its innovative technologies. By combining wearable biosensing technology with cloud-based data analytics and advanced machine learning capabilities, iRhythm aims to be the leading provider of first-line ambulatory electrocardiogram (ECG) monitoring, particularly for patients at risk of arrhythmias.
The company's flagship product, the Zio service, represents a comprehensive solution that includes an easy-to-wear biosensor capable of monitoring a patient's heart rhythm continuously for up to 14 days. This device, paired with the company's proprietary algorithms, transforms millions of heartbeats into clinically actionable data, significantly enhancing the diagnostic yield compared to traditional Holter monitors and other event monitoring systems. This approach not only expedites diagnosis but also reduces the need for repeat testing, thereby allowing timely medical intervention and potentially preventing severe outcomes like stroke.
Recent accomplishments highlight iRhythm's commitment to advancing cardiac care. The Zio monitor system has received the CE mark, underscoring its recognition as a leading innovation in ambulatory cardiac monitoring. The Zio monitor is designed to be thinner, lighter, and more discreet than its predecessor, the Zio XT, while improving patient compliance and monitoring accuracy. Furthermore, the company has integrated the ZEUS (Zio ECG Utilization Software) System, an advanced AI algorithm, to enhance data analysis and capture.
iRhythm's clinical research, such as the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events (CAMELOT) study, has demonstrated the superior diagnostic accuracy and lower retest rates of the Zio service. These findings, published in the American Heart Journal, indicate significant advantages in clinical utility and cost-effectiveness over other monitoring systems.
On the financial front, iRhythm has shown robust performance, with significant increases in gross profit driven by higher demand for Zio services. The company's strategic initiatives include expanding its market presence in Europe, strengthening customer engagement through digital tools, and launching new products. The recent closure of a substantial non-dilutive senior secured term loan facility ensures continued financial flexibility and supports iRhythm's growth ambitions.
With nearly 8 million reports posted since its inception, iRhythm remains focused on delivering better data, better insights, and better health outcomes. The company's relentless focus on patient care and strategic partnerships positions it well for sustained growth and innovation in the digital healthcare landscape.
iRhythm Technologies (NASDAQ: IRTC), a leader in digital health, presented transformative findings at the ACC.23/WCC conference concerning its Zio XT monitoring system. The CAMELOT study reveals Zio XT offers the highest diagnostic yield and quickest time to diagnosis for arrhythmias, alongside lower retesting and healthcare utilization rates compared to other monitors. The study analyzed Medicare data from 287,789 patients, establishing Zio XT’s superiority over Holter and other monitoring options. Other significant studies highlighted include comparisons of Zio XT to the next-generation Zio monitor, which showed improved patient comfort and performance.
iRhythm Technologies (NASDAQ: IRTC) announced the presentation of four new studies at the ACC.23/WCC conference, held from March 4-6, 2023, in New Orleans. These studies, including the significant CAMELOT study, assess the effectiveness of different cardiac monitoring services, enhancing iRhythm’s clinical evidence for its Zio products. The conference will feature key presentations, such as the real-world experience of the next-generation Zio monitor and comparative effectiveness of ambulatory monitors for arrhythmia diagnosis among Medicare beneficiaries. This research aims to improve patient outcomes and expand iRhythm's market presence.
iRhythm Technologies, Inc. (NASDAQ: IRTC) reported significant financial results for Q4 and full year 2022. Fourth quarter revenue increased by 37.7% to $112.6 million, driven by Zio XT volume and improved CMS reimbursement rates. Gross margin improved to 69.9%, while net loss narrowed to $20.2 million. For the full year, revenue grew 27.3% to $410.9 million, with a gross margin of 68.5%. However, the net loss rose to $116.2 million. For 2023, iRhythm projects revenue growth of 16% to 18%, anticipating between $475 million and $485 million. The company remains focused on operational growth and innovation.
iRhythm Technologies (NASDAQ:IRTC) is set to announce its financial results for the fourth quarter and full year 2022 on February 23, 2023, after market close. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. iRhythm is recognized for its innovative digital health solutions that utilize wearable biosensors and cloud analytics to deliver clinically actionable information. The upcoming earnings report is anticipated to provide insights into the company’s financial performance and strategic direction.
iRhythm Technologies (NASDAQ: IRTC) announced preliminary operational highlights for Q4 2022 at the J.P. Morgan Healthcare Conference. Patient registrations saw growth of over 20% year-over-year, and there was a record number of new Zio XT account openings in the U.S. The company improved its returned device rates, aligning closer to historical figures. The CMS Medicare Physician Fee Schedule for 2023 was released, providing relevant rates for reimbursement. iRhythm aims for sustainable growth in 2023 through strategic initiatives, including entering the primary care channel and launching a next-gen biosensor platform.
iRhythm Technologies (NASDAQ: IRTC) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. ET/1:30 p.m. PT. This leading digital healthcare company focuses on innovative solutions for disease detection, prediction, and prevention. The management presentation will be available via live and archived webcast on the company's Investors website. iRhythm combines wearable biosensors with advanced data analytics to deliver actionable health insights, aiming to improve patient outcomes.
iRhythm Technologies (NASDAQ: IRTC) presented four clinical studies at the American Heart Association 2022 Scientific Sessions showing significant value in their Zio® product lines for diagnosing cardiovascular issues. The studies highlighted the cost-effectiveness of atrial fibrillation (AF) screening using the Zio XT, reporting an incremental cost-effectiveness ratio of $17,000 per quality-adjusted life year. Additionally, data indicated that extended ECG monitoring improved accuracy in assessing premature ventricular contractions (PVC) and unveiled unexpected rates of AF in patients experiencing syncope.
iRhythm Technologies (NASDAQ:IRTC) announced a new health economic analysis from its mSToPS trial at the American Heart Association’s 2022 event, assessing the cost-effectiveness of AFib screening using the Zio XT patch. Findings revealed significant benefits, including increased outpatient visits and improved survival rates for patients monitored with Zio XT. The study demonstrated a cost-effectiveness ratio of $17,000 per quality-adjusted life year gained, lower than U.S. willingness-to-pay thresholds. The analysis indicates that systematic AFib screening offers substantial value in healthcare settings.
iRhythm Technologies (NASDAQ:IRTC) announced updates on the Centers for Medicare and Medicaid Services (CMS) Medicare Physician Fee Schedule (MPFS) for 2023, released on November 2, 2022. The updated reimbursement rates for long-term ECG monitoring services include $224 for CPT code 93247 and $213 for CPT code 93243. Estimated rates could range from $227 to $307 for 93247 and $216 to $292 for 93243 at iRhythm's diagnostic facilities. iRhythm views this as a significant milestone, improving access and stability for the company, though it expresses concerns that current rates may not fully reflect the clinical benefits of its Zio XT service.
iRhythm Technologies (NASDAQ:IRTC) reacted to the CMS announcement of the Medicare Physician Fee Schedule Final Rule for 2023. A key highlight is the new national pricing for certain CPT codes, with the price for the external ECG patch (SD339) increasing from $245.69 to $260.35. This positive adjustment may enhance iRhythm's reimbursement for its Zio® XT service, which relies on CPT codes 93243 and 93247. iRhythm will comment further once the Final Rule is published in the Federal Register.
FAQ
What is the current stock price of iRhythm Technologies (IRTC)?
What is the market cap of iRhythm Technologies (IRTC)?
What does iRhythm Technologies, Inc. do?
What is the Zio service?
What recent achievements has iRhythm made?
How does the Zio monitor compare to traditional Holter monitors?
What was the outcome of the CAMELOT study?
What financial initiatives has iRhythm undertaken recently?
What is ZEUS in the context of iRhythm's services?
How is iRhythm expanding its market presence?
What are iRhythm's future plans?
How can I learn more about iRhythm Technologies, Inc.?
